This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Insilico Medicine, Inc.
Insilico Medicine, Inc., a pioneering biotechnology firm headquartered in Hong Kong, is at the forefront of artificial intelligence-driven drug discovery and development. Founded in 2014, the company has rapidly established itself as a leader in the industry, leveraging advanced machine learning techniques to accelerate the drug development process. With a focus on areas such as ageing research and disease modelling, Insilico Medicine offers unique solutions that integrate AI with biology, enabling the identification of novel drug candidates and biomarkers. The company’s innovative platform has garnered significant attention, leading to partnerships with major pharmaceutical firms and academic institutions. Recognised for its contributions to the field, Insilico Medicine continues to push the boundaries of traditional drug discovery, positioning itself as a key player in the evolving landscape of biotechnology.
DitchCarbon Score
How does Insilico Medicine, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Insilico Medicine, Inc.'s score of 20 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Insilico Medicine, Inc.'s reported carbon emissions
Insilico Medicine, Inc., headquartered in Hong Kong, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges. As a result, there are no significant achievements or commitments to report regarding their carbon footprint or climate initiatives. The lack of emissions data and reduction strategies suggests that Insilico Medicine may still be in the early stages of developing a comprehensive climate action plan. In the context of the biotechnology industry, it is increasingly important for companies to adopt transparent climate commitments and set measurable targets to align with global sustainability goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Insilico Medicine, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
